Anlin Xu, MD
Allergy · San Jose, CANPI 1285681007
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,019 of the $15,813 with a category attached, or 88.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,818, 3.5 times the $1,085 reported in 2019.
Across 490 payments — averaging $32.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Genentech USA, Inc.$2K
- Sanofi$2K
- CSL Behring$585
- Amgen$560
- plus $4K from 29 others
What the payments were for
- Consulting fees$1,76011%
- Food & beverage$14,01989%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $3,149 |
| GSK | 145 | $3,123 |
| Genentech USA, Inc. | 30 | $2,298 |
| Sanofi | 53 | $1,617 |
| CSL Behring | 30 | $585 |
| Amgen(2 entities) | 19 | $560 |
| Novartis | 18 | $536 |
| Regeneron Healthcare Solutions, Inc. | 14 | $444 |
| ARS Pharmaceuticals Operations, Inc. | 16 | $406 |
| Teva Pharmaceuticals USA, Inc. | 9 | $332 |
| Pfizer | 15 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $257 |
| Organon | 6 | $242 |
| Incyte Corporation | 6 | $231 |
| Galderma Laboratories, L.p. | 4 | $217 |
| Sun Pharmaceutical Industries Inc. | 1 | $195 |
| Alk-abello, Inc | 8 | $179 |
| AbbVie(2 entities) | 3 | $166 |
| Boehringer Ingelheim | 6 | $165 |
| Lilly USA, LLC | 4 | $99 |
| LEO Pharma Inc. | 4 | $80 |
| Grifols Shared Services North America, Inc. | 1 | $72 |
| Circassia Inc. | 2 | $65 |
| Octapharma USA, Inc. | 2 | $64 |
| Kowa Pharmaceuticals America, Inc. | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $62 |
| Optinose US, Inc. | 3 | $56 |
| Kaleo, Inc. | 3 | $51 |
| Grifols USA, LLC | 2 | $50 |
| Ionis Pharmaceuticals, Inc. | 1 | $40 |
| Hospira, Inc. | 1 | $26 |
| Genentech, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| Covis Pharma GmbH | 1 | $22 |
| USWM, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,813 in reported general payments places this provider in the 80th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,222 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,683 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $527 |
| Montelukast Sodium | 16 | $431 |
| Triamcinolone Acetonide | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $3,123 | $16,22223 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $332 | $3,68313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 allergy providers in California.
Other allergy in San Jose
- John KelloggSan Jose$17K
- Alan HellerSan Jose$10K
- Theodore ChuSan Jose$10K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.